Revance Therapeutics | L'Utile Ante Imposte



L'Utile Ante Imposte Cambiamento Data
AbbVie USD 4.38B 1.92B 2025-09
ALKERMES USD 100.74M 4.1M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Cara Therapeutics USD -4.91M 3.17M 2025-03
Coherus Biosciences USD -47.4M 14.9M 2025-03
Eli Lilly USD 7.23B 456M 2025-09
J&J USD 4.97B 2.53B 2025-12
Merck USD 6.74B 22M 2025-09
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
P&G USD 5.42B 613M 2025-12
Pacira USD -1.93M 10.63M 2025-06
Supernus Pharmaceuticals USD -57.95M 74.62M 2025-09


Revance Therapeutics L'Utile Ante Imposte - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.